Core Viewpoint - The article discusses the strategic investment of Yan Jianya and Fan Daidi in the high-barrier commercial aerospace sector through the establishment of a joint venture, aiming to create a second growth curve outside the consumer sector [1] Group 1: Joint Venture and Investment - A joint venture named Western Aerospace Technology (tentative) is being established with a registered capital of 500 million yuan, focusing on the satellite and rocket field [1][3] - Triangle Defense, led by Yan Jianya, invested 200 million yuan to acquire 40% of the joint venture, becoming the largest shareholder [3] - The joint venture aims to cover the entire aerospace industry chain, including satellite design, rocket development, and data application [3] Group 2: Triangle Defense's Strategic Moves - Triangle Defense is extending its business from aerospace components to full industry chain coverage, marking a significant step in its aerospace strategy [3] - The company is also involved in a digital integration center project for the C919 aircraft, which is expected to enhance its manufacturing capabilities and competitive position in the domestic aerospace sector [3] Group 3: Other Partners in the Joint Venture - Western Testing, a partner in the joint venture, focuses on inspection and intelligent manufacturing services in aerospace and high-end equipment, proposing a "super OEM" model for commercial aerospace [4] - The Shaanxi Aerospace Institute, another partner, is a key state-owned research institution that connects core technologies with commercial markets [4] Group 4: Giant Biological's Growth Strategy - Giant Biological, under the leadership of Fan Daidi, is transitioning from a consumer goods company to a medical technology enterprise, leveraging regulatory approvals for high-value medical devices [6][7] - The company has received approvals for innovative medical products, positioning itself to compete directly with established players in the medical aesthetics market [6][7] Group 5: Global Expansion and Collaboration - Giant Biological is pursuing a "borrow the boat to go to sea" strategy by collaborating with international firms to expedite the global commercialization of its products [7] - This approach allows the company to avoid the lengthy process of building its own distribution channels while achieving direct monetization of its technology [7] Group 6: Market Position and Valuation - As of March 19, 2026, Giant Biological's stock price is 30.86 HKD, with a market capitalization of 33.05 billion HKD, indicating its significant market presence [8] - The combined efforts of Giant Biological and Triangle Defense create a stable dual-core structure for the investment strategy of Yan Jianya and Fan Daidi, balancing consumer and military/aerospace sectors [8]

Core Insights - The collagen market is experiencing strong consumer demand and awareness, with a current industry growth phase [1][2] - The number of registered products is increasing, but the supply is not yet fully meeting consumer demand, indicating a continued industry opportunity [1][2] - In the medium term, brands with strong product differentiation will be more competitive, relying on materials and technology [1][2] - Long-term competition will shift towards a combination of product, channel, and marketing strengths [1][2] Demand Perspective - Consumers have a strong recognition of collagen, leading to robust demand [1][2] - The aesthetic medicine injection market in China is projected to reach approximately 26.8 billion yuan in 2024, with a year-on-year growth of 26.4% [2] - The collagen product segment is expected to grow at a CAGR of 50.7% from 2024 to 2028 [2] Supply Perspective - The number of registered certificates for natural and recombinant collagen is on an upward trend, with a total of 10 certificates approved for 7 companies [3][4] - The current supply of collagen products is limited, with high prices and insufficient market penetration [2][4] - The market is expected to develop a product tier system with high (>10,000 yuan), medium (4,000-6,000 yuan), and low (500-2,000 yuan) price points to cater to diverse consumer needs [2] Product Differentiation - New products are expected to innovate around materials, indications, and concentrations, leading to differentiated pricing [4] - The majority of registered products are I-type collagen, with a focus on non-crosslinked and crosslinked types [3][4] - Future developments will likely focus on unique types and amino acid sequences, enhancing product differentiation [5] Market Dynamics - The industry is currently in a growth phase, with opportunities for companies to capture market share through innovation and strategic positioning [7] - Companies with strong R&D capabilities and marketing strategies are likely to succeed in the competitive landscape [7] - The market is anticipated to see an increase in registered products, enhancing the variety of indications and price tiers available [7]

Core Viewpoint - The technology and processes for natural collagen and recombinant collagen are continuously improving, leading to an expansion of application scenarios and an increase in the number of approved collagen products, which will enrich indications and enhance market penetration [1] Industry Summary - The number of registered certificates for natural collagen and recombinant collagen products is increasing but is still far from saturation, providing opportunities for various companies to share in the industry's growth [1] - The medical beauty market is expected to see an increase in both the number of consumers and market penetration as more collagen products are approved [1] Company Recommendations - The recombinant collagen freeze-dried fiber registration certificate is expected to be approved and launched in the first half of 2026, with recombinant collagen solutions and gels also anticipated to receive approval in 2026, potentially becoming a second growth curve for companies [1] - Companies entering the natural collagen field through acquisitions, with steady progress in the research and clinical development of related medical beauty Class III devices, are expected to gain approval in the future and become new forces in the existing medical beauty biomaterials matrix [1] - Companies with strong drug development and review experience that are simultaneously laying out natural and recombinant collagen through agency and self-research are well-positioned for growth [1]

Core Insights - The collagen market is experiencing significant changes with new product approvals from Chongshan Bio and Aibai Rui, expanding the range of certified products in the industry [1][3] - The competition in the animal-derived collagen segment is intensifying, with companies focusing on differentiation through high concentration and specific indications [3] - The recombinant collagen sector is expected to outpace animal-derived collagen in growth, driven by safety and scalability advantages [6][9] Group 1: Product Approvals and Market Dynamics - Chongshan Bio's new product is the world's first implant with a concentration of 45mg/ml, aiming to establish a competitive edge through high concentration [3] - Aibai Rui's product targets specific needs for improving facial smoothness, attempting to create a niche in the crowded market [3] - The number of certified collagen products in China has increased to 14, indicating a growing market but also heightened competition [8] Group 2: Competitive Landscape - The animal-derived collagen market has formed an "eight strong" competitive landscape, with established players like Shuangmei Bio leading due to their early market entry and established clinical safety [3] - New entrants are seeking differentiation through quality ingredients and innovative product forms, such as Fiman Bio's focus on safety and convenience [3][9] - The recombinant collagen market is projected to grow at a compound annual growth rate (CAGR) of 41.4% from 2023 to 2027, compared to 27.7% for animal-derived collagen [6] Group 3: Industry Trends and Future Outlook - The rise of recombinant collagen is attributed to its technological advantages, which mitigate risks associated with animal-derived products [6] - Companies are increasingly focusing on upstream raw material preparation and core production technologies to enhance product quality and safety [9] - The market is expected to see a surge in collagen product offerings in the next two years, as more companies enter the recombinant collagen space [8][9]